RMRK
8.6.2021 15:32:07 CEST | Business Wire | Press release
RMRK , an advanced NFT protocol project, announced today that it raised 6 million USD to build the standard cross-chain NFT infrastructure in the Polkadot and Kusama ecosystem. Investors such as D1 Ventures , YBB , PAKA , DFG , and others are all betting on NFTs 2.0 as presented by RMRK.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005768/en/
“NFTs right now are digital-dust-gathering assets, mainly overpriced digital pictures that you keep in your digital wallet until the next NFT hype wave hits.” says Bruno Škvorc, project founder and Web3 Foundation alum. “We believe that they’re meant for much more than that. NFTs can have long lasting liquidity by being upgradable, nestable within other NFTs, by being able to react to people reacting to them with emotes, and by being democratically governed through fractional ownership!”
By launching a gamified “initial collectible offering” called Kanaria on Kusama even without smart contracts, the RMRK team has pioneered the NFT-crowdfunding approach which netted them a total of 2 million USD in limited edition egg-nft sales. All egg buyers will also be entitled to a fairdrop of the coming $RMRK token. The remaining 4 million were raised directly from investors based on the vision of NFTs 2.0.
NFTs 2.0
RMRK is developing new standards to expand what NFTs can do:
● NFTs that can own other NFTs
● NFTs that can listen to commands or issue them to their children
● NFTs as DAOs that can, through fractional ownership, be controlled by a group
● NFTs that can react to emotion with conditional rendering logic (send 50 rocket emoji to a picture of a moon, and it can show you a moonbase)
● NFTs that can have multiple resources at once (mint an e-book with an audio version, a PDF file, and a high resolution cover - the environment it’s loaded in decides which part to load automatically).
With these “art legos” in place, RMRK has created an NFT operating system that makes possible NFT projects of arbitrary complexity .
Powerful Partnerships
This potential of art legos was recognized by key players in the Kusama and Polkadot ecosystem, as documented on RMRK’s official blog . Rather than crowd the already crowded parachain space, RMRK has opted to add their technology to other chains instead - the project’s very first runtime-based deployment will be with Unique Network , a dedicated NFT parachain project in the Kusama and Polkadot ecosystem.
With RMRK’s logic coming into the runtime functionality of several partner chains, the RMRK standards for NFTs 2.0 are poised to become the first shared-runtime environment in the Polkadot ecosystem, allowing for seamless teleportation of non fungible assets to and from any supported chain, natively, and at almost zero cost.
You can learn more about RMRK at rmrk.app , and you can play around with their official minting and trading UI for NFTs called Singular on singular.rmrk.app . Reach out to the team at hello@rmrk.app , on Telegram , or on Twitter , and read their blog on Subsocial .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005768/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
